Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Immune checkpoint inhibitors (ICIs) are vital cancer treatments but can induce colitis, a condition mimicking inflammatory bowel disease (IBD).
• The precise pathogenesis of ICI-induced colitis, involving regulatory T cells and the gut microbiome, remains under investigation.
• Accurate diagnosis through endoscopic and histopathological evaluation is crucial, distinguishing it from IBD.

Purpose of the Study:

• To explore biologic therapeutic strategies for managing refractory immune checkpoint inhibitor-induced colitis.
• To provide an overview of current guidelines, challenges, and suggested protocols for immunosuppressive drug management in these cases.

Main Methods:

• This study is a review of existing literature on immune checkpoint inhibitor-induced colitis.
• It synthesizes information on diagnostic methods, pathogenesis, and therapeutic interventions, focusing on biologic agents.
• The review also addresses challenges in management and proposes protocols for drug immunosuppression.

Main Results:

• ICI-induced colitis exhibits unique characteristics distinct from IBD, influenced by regulatory T cells and gut microbiota.
• Corticosteroids are the initial treatment, but refractory cases require advanced therapeutic approaches.
• Biologic therapies offer promising perspectives for managing severe or refractory ICI-induced colitis.

Conclusions:

• Effective management of ICI-induced colitis necessitates collaboration between gastroenterologists and oncologists.
• Further research into the unique mechanisms of ICI-induced colitis is essential for refining treatment strategies.
• Biologic therapies represent a key area for developing advanced treatment protocols for refractory cases.